<DOC>
	<DOCNO>NCT00488215</DOCNO>
	<brief_summary>An escalate dose prucalopride maximum 20 mg give daily 32 healthy volunteer determine safety maximum tolerable dose 20 mg .</brief_summary>
	<brief_title>A Trial Healthy Volunteers , Evaluate Tolerability Cardiac Safety Prucalopride</brief_title>
	<detailed_description>This single-centre , double-blind , placebo-controlled , cross-over trial 32 healthy volunteer two session ( I II ) . Each session consist run-in day baseline assessment , 13 treatment day 5 additional day assessment . Subjects randomize start either prucalopride placebo session . Between 2 session , washout period 14 21 day , avoid carry-over effect .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>1 . Aged 18 45 year , extremes include . 2 . Subject normal weight define Quetelet Index range 18 30 kg/m2 , extremes include . 3 . Informed consent form sign date , prior screening . 4 . Healthy basis pretrial physical examination , medical history , anamnesis , electrocardiogram , 24 hour Holter monitoring result blood biochemistry haematology test urinalysis carry 3 week precede randomization . 1 . History suspicion alcohol , barbiturate , amphetamine narcotic abuse . 2 . Smoking 10 cigarette , 2 cigar , 2 pipe per day least 6 month prior selection . 3 . History cardiac arrhythmia 's , bronchospastic cardiovascular disease ( e.g . ischemic heart disease cerebrovascular accident ) , diabetes mellitus , thyrotoxicosis , Parkinsonism , drug allergy . 4 . Presence prolong QTc ( Bazett ) ECG screening ( QTc &gt; 450 msec male subject , QTc &gt; 470 msec female subject ) . 5 . Use concomitant medication , except oral contraceptive paracetamol . All medication must stop least 14 day first dose . 6 . Participation investigational drug trial 30 day prior first visit . 7 . Donation blood 60 day precede first visit . 8 . Pregnancy ( confirm HCG test screen day 0 treatment session ) breastfeed female . 9 . Subjects positive result HIV , hepatitis B C screening . 10 . Female subject childbearing potential without adequate contraceptive protection trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>constipation</keyword>
	<keyword>prucalopride</keyword>
	<keyword>MTD</keyword>
	<keyword>cardiovascular safety</keyword>
</DOC>